Ceftazidime labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Labels and packaging== | ==Labels and packaging== | ||
===FORTAZ=== | ===FORTAZ=== | ||
{| | |||
| [[image:Fortaz.jpg|400px|thumb]] | |||
|} | |||
===TAZICEF=== | ===TAZICEF=== | ||
[[image: | {| | ||
| [[image:Tazicef.jpg|400px|thumb]] | |||
|} | |||
{| | |||
[[image: | | [[image:Tazicef1.jpg|400px|thumb]] | ||
|} | |||
[[image:Tazicef4.jpg]] | {| | ||
| [[image:Tazicef2.jpg|400px|thumb]] | |||
|} | |||
{| | |||
| [[image:Tazicef3.jpg|400px|thumb]] | |||
|} | |||
{| | |||
| [[image:Tazicef4.jpg|400px|thumb]] | |||
|} | |||
===CEFTAZIDIME injection=== | ===CEFTAZIDIME injection=== | ||
[[image:Ceftainj1.jpg]] | {| | ||
| [[image:Ceftainj1.jpg|400px|thumb]] | |||
|} | |||
==References== | ==References== | ||
Latest revision as of 18:45, 30 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Labels and packaging
FORTAZ
 |
TAZICEF
 |
 |
 |
 |
 |
CEFTAZIDIME injection
 |
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050578s053,050634s020lbl.pdf